Financial terms include $40 million upfront for four programs, expansion options, and opt-out economics up to $535 million per program plus low double-digit royalties, totaling up to $2.1 billion.

Drug developers weigh building internal radiopharmaceutical capabilities versus outsourcing amid timeline and funding uncertainties in the sector.

European authorities have recommended changes to the regulatory framework to keep pace with the progress of the ...

Cancer innovation advances in many ways, but real impact depends on the ability to translate progress into care that is ...